Conversation with The Cancer LetterFree Rita Redberg: FDA proposal to delay reporting of device malfunctions “should be tossed” July 28, 2017Vol.43 No.30By Matthew Bin Han Ong
Conversation with The Cancer Letter Will Parsons: This is a fantastic opportunity to test precision oncology for pediatric patients in a large-scale way July 28, 2017Vol.43 No.30By Paul Goldberg
Pediatric MATCH starts to accrue children with recurrent and refractory cancers July 28, 2017Vol.43 No.30By Paul Goldberg
Free Anti-morcellation advocate files “wrongful death” suit against Karl Storz and Brigham & Women’s Hospital July 21, 2017Vol.43 No.29By Matthew Bin Han Ong
FreeGuest Editorial Medical research funding: Why we must keep our foot on the accelerator July 21, 2017Vol.43 No.29By Michael A. Caligiuri
Conversation with The Cancer LetterFree Klausner: CRUK Grand Challenge—more than just another grant July 21, 2017Vol.43 No.29By Paul Goldberg
Free Cancer Research UK awarding £20 million Grand Challenge grants to cancer researchers worldwide July 21, 2017Vol.43 No.29By Paul Goldberg
ODAC unanimously recommends approval for CAR T-cell therapy for relapsed and refractory B-cell ALL in kids and young adults July 14, 2017Vol.43 No.28By Claire Dietz and Paul Goldberg
Removed from U.S. market in 2011, Pfizer’s Mylotarg slated to return following results of a French study that tested a new regimen July 14, 2017Vol.43 No.28By Paul Goldberg
FY18 health budget battle begins: House appropriators slate $1.1 billion increase for NIH while defunding ACA, Title X July 14, 2017Vol.43 No.28By Matthew Bin Han Ong
